Hubert Kübler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hubert Kübler has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Jürgen E. Gschwend
Technische Universität München
6 shared publications - Tobias Maurer
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
6 shared publications - Gregor Weirich
Department of Pathology, Munich, Germany
5 shared publications - Markus Schwaiger
Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
4 shared publications - Matthias Eiber
Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany
3 shared publications - Thomas Horn
Technische Universität München
3 shared publications
Latest Publications
- 28 March 2022
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 53 (02) , 97
Editorial
Liebe Kolleginnen und Kollegen, liebe Leser*innen, als erstes möchte ich mich beim Thieme-Verlag und den Herausgebern bedanken, dass Sie mir das Vertrauen schenken, als Mitherausgeber in die Fußstapfen von Professor Kurt Miller treten zu können. Kurt Miller hat nicht nur über viele Jahre hinweg die Aktuelle Urologie gestaltet, sondern mich auch auf meinem beruflichen Weg mit Rat und Tat begleitet. An dieser Stelle möchte ich mich den Leser*innen der Aktuellen Urologie näher vorstellen. Nach dem Studium der Humanmedizin an der Universität in Ulm habe ich als Arzt im Praktikum an der Urologischen Klinik des Klinikums rechts der Isar in München unter der Leitung Professor Rudolf Hartung meine klinische Karriere begonnen und dort auch meinen Facharzt absolviert. Anschließend war ich für 2 Jahre als Research Associate am Genitourinary Cancer Immunotherapy Program der Duke University in Durham, North Carolina, unter der Leitung von Professor Johannes Vieweg tätig. Diese wissenschaftlichen Erfahrungen bildeten die Basis für meine Habilitation über onkologische Vakzinierungsstrategien mit Dendritischen Zellen an der Technischen Universität München. Meine weitere klinische Karriere war durch die langjährige Tätigkeit bei Professor Jürgen Gschwend geprägt. So ist es nicht verwunderlich, dass mein persönlicher Schwerpunkt die Uroonkologie von operativen Techniken, über medikamentöse Therapieansätze bis translationale Fragestellungen darstellt. 2017 wurde ich auf den Lehrstuhl für Urologie und Kinderurologie der Julius-Maximilians-Universität Würzburg berufen. Mit dieser klinischen und wissenschaftlichen Expertise freue ich mich zusammen mit den Herausgebern die Aktuellen Urologie zukünftig gestalten zu können. Herzlichst Ihr Hubert Kübler Publication Date: 28 March 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 28 March 2022
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 53 (02) , 97
Editorial
Liebe Kolleginnen und Kollegen, liebe Leser*innen, als erstes möchte ich mich beim Thieme-Verlag und den Herausgebern bedanken, dass Sie mir das Vertrauen schenken, als Mitherausgeber in die Fußstapfen von Professor Kurt Miller treten zu können. Kurt Miller hat nicht nur über viele Jahre hinweg die Aktuelle Urologie gestaltet, sondern mich auch auf meinem beruflichen Weg mit Rat und Tat begleitet. An dieser Stelle möchte ich mich den Leser*innen der Aktuellen Urologie näher vorstellen. Nach dem Studium der Humanmedizin an der Universität in Ulm habe ich als Arzt im Praktikum an der Urologischen Klinik des Klinikums rechts der Isar in München unter der Leitung Professor Rudolf Hartung meine klinische Karriere begonnen und dort auch meinen Facharzt absolviert. Anschließend war ich für 2 Jahre als Research Associate am Genitourinary Cancer Immunotherapy Program der Duke University in Durham, North Carolina, unter der Leitung von Professor Johannes Vieweg tätig. Diese wissenschaftlichen Erfahrungen bildeten die Basis für meine Habilitation über onkologische Vakzinierungsstrategien mit Dendritischen Zellen an der Technischen Universität München. Meine weitere klinische Karriere war durch die langjährige Tätigkeit bei Professor Jürgen Gschwend geprägt. So ist es nicht verwunderlich, dass mein persönlicher Schwerpunkt die Uroonkologie von operativen Techniken, über medikamentöse Therapieansätze bis translationale Fragestellungen darstellt. 2017 wurde ich auf den Lehrstuhl für Urologie und Kinderurologie der Julius-Maximilians-Universität Würzburg berufen. Mit dieser klinischen und wissenschaftlichen Expertise freue ich mich zusammen mit den Herausgebern die Aktuellen Urologie zukünftig gestalten zu können. Herzlichst Ihr Hubert Kübler Publication Date: 28 March 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 1 January 2020
- Published by XMLink in The World Journal of Men's Health
- Vol. 38 (4) , 564-572
Long-Term Results after Surgical Treatment of Congenital Penile Curvature Using a Modified Nesbit Technique
Sokolakis I, et al. World J Mens Health. 2019 Jan;37:e52. https://doi.org/10.5534/wjmh.190092
- 1 January 2020
- Published by XMLink in The World Journal of Men's Health
- Vol. 38 (4) , 564-572
Open AccessLong-Term Results after Surgical Treatment of Congenital Penile Curvature Using a Modified Nesbit Technique
Sokolakis I, et al. World J Mens Health. 2019 Jan;37:e52. https://doi.org/10.5534/wjmh.190092
- 1 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (8) , e3089
MicroRNA-205 driven rewiring of cholesterol biosynthesis identifies therapeutic windows in aggressive prostate cancer
- 1 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (8) , e3089
MicroRNA-205 driven rewiring of cholesterol biosynthesis identifies therapeutic windows in aggressive prostate cancer
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1340
SQLE, a miR-205 dependent cholesterol biosynthesis regulator, is a druggable target in prostate cancer
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1340
SQLE, a miR-205 dependent cholesterol biosynthesis regulator, is a druggable target in prostate cancer
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , e16038
PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA.
E16038 Background: Prostate-specific membrane antigen (PSMA) shows increased expression on most prostate cancers (PCa). Aim of this retrospective analysis of consecutive pts was to evaluate the accuracy of Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] (68Ga-HBED-PSMA) a recently developed ligand of PSMA, for the preoperative staging of lymph node (LN) involvement in primary PCa. Methods: 92 consecutive pts with intermediate to high-risk PCa received 68Ga-HBED-PSMA-PET/MR and were included in this analysis. One nuclear medicine physician and one radiologist reviewed PET/MRI imaging in consensus. Pelvine LN dissection was performed according to a predefined template. LN involvement was evaluated according to a 5-point scale on a patient- and field-based manner and correlated to postoperative histological analysis. Results: Due to lacking PSMA expression of the primary PCa 4 pts were excluded from further analysis. In total, 20 pts showed metastatic LN. 68Ga-HBED-PSMA-PET/MR detected 15 out of 20 pts with histolo...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , e16038
PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA.
E16038 Background: Prostate-specific membrane antigen (PSMA) shows increased expression on most prostate cancers (PCa). Aim of this retrospective analysis of consecutive pts was to evaluate the accuracy of Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] (68Ga-HBED-PSMA) a recently developed ligand of PSMA, for the preoperative staging of lymph node (LN) involvement in primary PCa. Methods: 92 consecutive pts with intermediate to high-risk PCa received 68Ga-HBED-PSMA-PET/MR and were included in this analysis. One nuclear medicine physician and one radiologist reviewed PET/MRI imaging in consensus. Pelvine LN dissection was performed according to a predefined template. LN involvement was evaluated according to a 5-point scale on a patient- and field-based manner and correlated to postoperative histological analysis. Results: Due to lacking PSMA expression of the primary PCa 4 pts were excluded from further analysis. In total, 20 pts showed metastatic LN. 68Ga-HBED-PSMA-PET/MR detected 15 out of 20 pts with histolo...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 5023
PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy.
5023 Background: Staging of recurrent prostate cancer (PCa) after radical prostatectomy (RP) remains challenging especially at low PSA values. Prostate-specific membrane antigen (PSMA) shows increased expression on most PCa and might therefore be useful for detection of PCa lesions. Aim of this retrospective analysis of consecutive pts was to evaluate the detection rate of PET hybrid imaging using the PSMA inhibitor Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] (68Ga-HBED-PSMA) in pts with biochemical recurrence (BCR) of PCa after RP. Methods: 332 consecutive pts with BCR of PCa after RP and a median PSA value of 1.7 ng/ml (range 0.2-63 ng/ml) were included in this analysis. After injection of 122±17 MBq 68Ga-HBED-PSMA-PET/CT or PET/MR was performed in 256 pts and 76 pts, respectively. One nuclear medicine physician and one radiologist reviewed imaging in consensus. Detection rates according to PSA value were determined. Results: In total, detection rates for 68Ga-HBED-PSMA-PET hybrid imaging were 96.0% (143/1...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 5023
PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy.
5023 Background: Staging of recurrent prostate cancer (PCa) after radical prostatectomy (RP) remains challenging especially at low PSA values. Prostate-specific membrane antigen (PSMA) shows increased expression on most PCa and might therefore be useful for detection of PCa lesions. Aim of this retrospective analysis of consecutive pts was to evaluate the detection rate of PET hybrid imaging using the PSMA inhibitor Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] (68Ga-HBED-PSMA) in pts with biochemical recurrence (BCR) of PCa after RP. Methods: 332 consecutive pts with BCR of PCa after RP and a median PSA value of 1.7 ng/ml (range 0.2-63 ng/ml) were included in this analysis. After injection of 122±17 MBq 68Ga-HBED-PSMA-PET/CT or PET/MR was performed in 256 pts and 76 pts, respectively. One nuclear medicine physician and one radiologist reviewed imaging in consensus. Detection rates according to PSA value were determined. Results: In total, detection rates for 68Ga-HBED-PSMA-PET hybrid imaging were 96.0% (143/1...
- 20 March 2015
- Published by Elsevier in European Urology Supplements
- Vol. 14 (2) , e675
675 Introduction of PSMA-radioguided surgery in patients with recurrent prostate cancer: Taking salvage lymphadenectomy to the next level?
- 20 March 2015
- Published by Elsevier in European Urology Supplements
- Vol. 14 (2) , e675
675 Introduction of PSMA-radioguided surgery in patients with recurrent prostate cancer: Taking salvage lymphadenectomy to the next level?
- 11 January 2014
- Published by Springer Nature
- p. 253-259
Salvage Prostatectomy After Radiotherapy
- 26 May 2013
- Published by Springer Nature in World Journal of Urology
- Vol. 32 (2) , 359-363
The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancer
To determine GFR with different methods in patients with first-line chemotherapy for advanced urothelial cancer (UC) and to evaluate the impact of these methods on the estimation of cisplatin eligibility. A database was built retrospectively containing all patients receiving first-line chemotherapy for UC between 2001 and 2012 in one German high-volume center. GFR was calculated with the methods by Cockcroft–Gault (CG), MDRD and CKD-EPI. Measurements of creatinine clearance with timed urine collections were registered. A total of 166 patients were included. All methods of renal function determination yielded consistent results in terms of cisplatin eligibility for 134 patients (80.7 %) and disagreeing results for 32 patients (19.3 %). Twenty-two of these 32 patients with borderline GFR received cisplatin-based chemotherapy. Fifteen of these 22 patients completed at least three cycles. The mean GFR in the mentioned 32 patients was 51.3, 56.2 and 54.2 ml/min with the method by CG, MDRD and CKD-EPI. Three, ten and four patients were estimated cisplatin-eligible with either method. There was a good correlation between MDRD and CKD-EPI (r 2 = 0.92). CG tended to underestimate GFR compared to both MDRD and CKD-EPI. Measurements of creatinine clearance showed a wide distribution in comparison with MDRD (r 2 = 0.002). The method used to determine GFR influences the estimation of cisplatin eligibility in a subset of UC patients. MDRD and CKD-EPI formulas seem most valuable, while CG tends to underestimate renal function. Using a strict cutoff of 60 ml/min may unnecessarily preclude cisplatin in some patients.
- 26 May 2013
- Published by Springer Nature in World Journal of Urology
- Vol. 32 (2) , 359-363
The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancer
To determine GFR with different methods in patients with first-line chemotherapy for advanced urothelial cancer (UC) and to evaluate the impact of these methods on the estimation of cisplatin eligibility. A database was built retrospectively containing all patients receiving first-line chemotherapy for UC between 2001 and 2012 in one German high-volume center. GFR was calculated with the methods by Cockcroft–Gault (CG), MDRD and CKD-EPI. Measurements of creatinine clearance with timed urine collections were registered. A total of 166 patients were included. All methods of renal function determination yielded consistent results in terms of cisplatin eligibility for 134 patients (80.7 %) and disagreeing results for 32 patients (19.3 %). Twenty-two of these 32 patients with borderline GFR received cisplatin-based chemotherapy. Fifteen of these 22 patients completed at least three cycles. The mean GFR in the mentioned 32 patients was 51.3, 56.2 and 54.2 ml/min with the method by CG, MDRD and CKD-EPI. Three, ten and four patients were estimated cisplatin-eligible with either method. There was a good correlation between MDRD and CKD-EPI (r 2 = 0.92). CG tended to underestimate GFR compared to both MDRD and CKD-EPI. Measurements of creatinine clearance showed a wide distribution in comparison with MDRD (r 2 = 0.002). The method used to determine GFR influences the estimation of cisplatin eligibility in a subset of UC patients. MDRD and CKD-EPI formulas seem most valuable, while CG tends to underestimate renal function. Using a strict cutoff of 60 ml/min may unnecessarily preclude cisplatin in some patients.